Regulation of gonadal and somatotropic axis by chronic intraventricular infusion of insulin-like growth factor 1 antibody at the initiation of puberty in male rats.
There has been increasing experimental evidence to suggest that insulin-like growth factor 1 (IGF-I) may be one of the essential regulators in the reproductive system of the rat. IGF-I is synthesized in the hypothalamus and IGF-I immunoreactivity increases during puberty. Consequently we hypothesized that centrally located IGF-I might contribute to the initiation of puberty. Centrally located IGF-I was immunoneutralized to assess this hypothesis. Male Wistar rats, 28 days old, were infused intracerebroventricularly with specific purified IgGs from rabbit IGF-I antiserum (IGF-I-Ab). The intracerebroventricular administration of IGF-I-Ab resulted in a reduction in testicular weight and consequently in delayed pubertal development. There was also a reduction in serum testosterone, pituitary immunoreactive (IR) luteinizing hormone (LH) and serum IR follicle-stimulating hormone (FSH). The accumulation of betaLH mRNA was not modified, whereas betaFSH mRNA was increased. An increment in the serum growth hormone (GH) levels was also observed. There were no significant alterations in hypothalamic IR growth hormone releasing factor content, although IR somatostatin (SRIH) content was increased by IGF-I-Ab. The body weight gain remained unaltered. As a whole, our study suggests that centrally located IGF-I influences pubertal development, production and release of gonadotropins and supports the finding that endogenous centrally located IGF-I plays a role at the initiation of puberty in the male rat. It also gives support to the physiological role of centrally located IGF-I in the release of GH mediated by hypothalamic SRIH at the initiation of puberty.
Pazos
F
F
Endocrinology Services, Hospital Ramón y Cajal, Madrid, Spain. ferpato@ctv.es
Sánchez-Franco
F
F
Balsa
J
J
López-Fernandez
J
J
Escalada
J
J
Cacicedo
L
L
D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006062:Gonadotropins / Q000378:metabolism; D013006:Growth Hormone / Q000502:physiology*; D007031:Hypothalamus / Q000187:drug effects / Q000502:physiology; D017403:In Situ Hybridization; D007276:Injections, Intraventricular; D007334:Insulin-Like Growth Factor I / Q000276:immunology*; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D009929:Organ Size / Q000187:drug effects; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D012741:Sexual Maturation / Q000187:drug effects / Q000502:physiology*; D013004:Somatostatin / Q000378:metabolism; D013737:Testis / Q000502:physiology*
D000906:Antibodies; D006062:Gonadotropins; D012333:RNA, Messenger; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone